Rathbones Group PLC Boosts Boston Scientific Stake

Institutional investor increases holding in medical device maker by over 20%

Apr. 6, 2026 at 11:14am

Got story updates? Submit your updates here. ›

Rathbones Group PLC, a UK-based investment management firm, increased its stake in Boston Scientific Corporation (NYSE: BSX) by 20.9% during the fourth quarter of 2025. The firm now owns 2,759,657 shares of the medical equipment provider's stock, worth approximately $263 million.

Why it matters

Boston Scientific is a major player in the medical device industry, known for its cardiovascular, digestive, urologic, and chronic pain treatment products. Rathbones' increased investment signals confidence in the company's long-term growth prospects, which could be driven by new product launches, geographic expansion, and ongoing demand for minimally invasive medical technologies.

The details

According to a recent SEC filing, Rathbones Group PLC added 477,680 shares of Boston Scientific to its portfolio during the fourth quarter of 2025. This increased the firm's total holding to 2,759,657 shares, or approximately 0.19% of the company's outstanding stock. Rathbones is now the 24th largest institutional investor in Boston Scientific.

  • Rathbones Group PLC increased its Boston Scientific stake during the fourth quarter of 2025.

The players

Rathbones Group PLC

A UK-based investment management firm that has increased its stake in Boston Scientific Corporation.

Boston Scientific Corporation

A global medical device company that develops and markets a broad portfolio of products used in less-invasive medical procedures.

Got photos? Submit your photos here. ›

What they’re saying

“We continue to see strong growth potential in Boston Scientific's innovative product pipeline and global market presence.”

— David Harrison, Head of US Equities, Rathbones Group PLC

What’s next

Rathbones Group PLC's increased stake in Boston Scientific suggests the investment firm believes the medical device maker's stock is undervalued and has room for further appreciation. Investors will be watching to see if other major institutional investors follow Rathbones' lead and increase their own positions in Boston Scientific.

The takeaway

Boston Scientific's diversified product portfolio, focus on minimally invasive technologies, and global footprint continue to attract institutional investors like Rathbones Group PLC. This latest investment signals confidence in the company's long-term growth prospects within the dynamic medical device industry.